Syndax Pharmaceuticals Cash Per Share vs. Price To Earning

SNDX Stock  USD 19.71  0.18  0.90%   
Based on Syndax Pharmaceuticals' profitability indicators, Syndax Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Syndax Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
8.22123306
Current Value
8.63
Quarterly Volatility
3.40391123
 
Credit Downgrade
 
Yuan Drop
 
Covid
Operating Cash Flow Sales Ratio is likely to rise to 0.25 in 2024, whereas Price To Sales Ratio is likely to drop 6.97 in 2024. At this time, Syndax Pharmaceuticals' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 21.6 M in 2024, despite the fact that Operating Income is likely to grow to (218.5 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
For Syndax Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Syndax Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Syndax Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Syndax Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Syndax Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.40)
Revenue Per Share
0.045
Quarterly Revenue Growth
332.974
Return On Assets
(0.40)
Return On Equity
(0.63)
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Syndax Pharmaceuticals Price To Earning vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Syndax Pharmaceuticals is rated below average in cash per share category among its peers. It is currently regarded as top stock in price to earning category among its peers reporting about  21.67  of Price To Earning per Cash Per Share. At this time, Syndax Pharmaceuticals' Cash Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Syndax Price To Earning vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Syndax Pharmaceuticals

Cash Per Share

 = 

Total Cash

Average Shares

 = 
5.82 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Syndax Pharmaceuticals

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
126.11 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Syndax Price To Earning Comparison

Syndax Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Syndax Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Syndax Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Syndax Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Syndax Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Syndax Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income218 K228.9 K
Operating Income-230 M-218.5 M
Income Before Tax-209.4 M-198.9 M
Total Other Income Expense Net20.6 M21.6 M
Net Loss-209.4 M-198.9 M
Income Tax Expense-5 M-4.8 M
Net Loss-176.1 M-167.3 M
Net Loss-134.4 M-127.7 M
Interest Income18.6 M19.5 M
Net Interest Income18.4 M19.3 M
Non Operating Income Net Other695.8 K730.5 K
Change To Netincome16.1 M8.2 M
Net Loss(2.98)(3.13)
Income Quality 0.77  0.63 
Net Income Per E B T 1.11  1.09 

Syndax Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Syndax Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Syndax Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Syndax Pharmaceuticals' important profitability drivers and their relationship over time.

Use Syndax Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syndax Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Syndax Pharmaceuticals Pair Trading

Syndax Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Syndax Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syndax Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syndax Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syndax Pharmaceuticals to buy it.
The correlation of Syndax Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syndax Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syndax Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syndax Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Syndax Pharmaceuticals position

In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Social Domain Thematic Idea Now

Social Domain
Social Domain Theme
New or established large and mid-sized companies that are involved in the social media industry, including entities that provide web-based or mobile media applications and services across across large segment of population in multiple geographical areas. The Social Domain theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Social Domain Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.